A synthetic tetrapeptide based on the pineal gland extract epithalamin that promotes telomere elongation and demonstrates significant longevity effects in animal models.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Epithalon is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (alanine-glutamic acid-aspartic acid-glycine) that serves as a laboratory-synthesized analog of epithalamin, a polypeptide extract derived from the pineal gland. Its development emerged from decades of research by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, where the biological activity of peptides extracted from various endocrine and immune organs was systematically investigated beginning in the 1970s. The pineal gland, long associated primarily with melatonin production and circadian rhythm regulation, yielded an extract that demonstrated remarkable effects on aging biomarkers in both animal studies and ultimately in human research — and Epithalon was synthesized as the active principle responsible for those effects.
The molecular simplicity of Epithalon — just four amino acids, molecular weight approximately 390 daltons — belies a complex biological activity profile centered on what may be one of the most consequential mechanisms in cellular aging research: the regulation of telomerase, the enzyme responsible for maintaining telomere length at chromosome ends. Telomeres are the protective repetitive DNA sequences (TTAGGG repeats in humans) that cap chromosomes, preventing end-degradation and chromosome fusion. With each cell division, a small segment of telomeric DNA is lost due to the “end replication problem” inherent in DNA polymerase mechanics; over time, telomere shortening reaches a critical threshold that triggers cellular senescence or apoptosis. Telomerase, the reverse transcriptase that synthesizes new telomeric repeats, can counteract this process — and in normal somatic cells, its expression is very low, meaning telomere shortening proceeds largely unchecked. Epithalon’s ability to upregulate telomerase activity has positioned it at the center of a research field examining whether pharmacological extension of cellular lifespan is achievable.
Beyond telomere biology, Epithalon’s derivation from the pineal gland extract gives it biological activities connected to that organ’s broader functions: regulation of melatonin biosynthesis, modulation of the hypothalamic-pituitary-gonadal axis, antioxidant enzyme regulation, and circadian rhythm synchronization. Khavinson’s group documented effects on life span extension in multiple animal species and, in a series of studies that remain remarkable for their ambition and scope, reported effects on longevity and cancer incidence in elderly human subjects enrolled in decades-long observational and intervention studies.
The regulatory and approval status of Epithalon differs from most peptides discussed in research contexts: it exists in a gray zone where it has been extensively published and clinically investigated in Russia but has not undergone FDA or EMA regulatory review for pharmaceutical approval. It is not approved in Western regulatory frameworks, meaning all use in those jurisdictions occurs in the research context. The quality and quantity of published peer-reviewed literature on Epithalon — much of it authored by Khavinson’s group — is unusual for a compound without Western regulatory standing, numbering in the dozens of papers across multiple decades and research domains.
The centerpiece of Epithalon’s proposed mechanism in cellular aging is its ability to activate telomerase, specifically through upregulation of hTERT — the catalytic subunit of the human telomerase holoenzyme. In most normal somatic cells, hTERT transcription is epigenetically silenced; the promoter region of the hTERT gene is densely methylated and associated with repressive histone modifications, effectively keeping telomerase expression at very low basal levels. The consequence, as noted above, is progressive telomere shortening with each cell division, ultimately driving cells into replicative senescence.
Cell culture studies examining the effect of Epithalon on somatic cell lines have found dose-dependent increases in hTERT mRNA levels and telomerase enzymatic activity (typically assayed using the TRAP assay, which measures the ability of cellular extracts to extend telomeric primer sequences in vitro). Crucially, these studies have documented actual elongation of mean telomere length in Epithalon-treated cell populations compared to controls over extended culture periods — providing functional evidence that the activated telomerase is working on chromosomal telomeres rather than simply existing as a biochemical curiosity. The molecular mechanism linking Epithalon binding to hTERT transcriptional upregulation has not been fully characterized; working hypotheses include chromatin remodeling effects on the hTERT promoter, transcription factor recruitment, or interaction with regulatory elements of the telomerase regulatory network. Studies in fibroblasts from elderly donors have found that Epithalon treatment allowed these normally post-mitotic cells to exceed their Hayflick limit — dividing more times than control cells of the same donor origin — consistent with telomerase-mediated lifespan extension at the cellular level.
The pineal gland’s core function — synthesis and secretion of melatonin in a circadian pattern driven by light/dark signals from the suprachiasmatic nucleus — undergoes progressive decline with aging. Pineal calcification, reduced pinealocyte number and activity, and diminished responsiveness to circadian input signals all contribute to the well-documented decline in melatonin amplitude and night-time peak concentration in elderly individuals. This decline has broad consequences: melatonin is not only a sleep-promoting signal but also a direct antioxidant (particularly effective at neutralizing hydroxyl and peroxy radicals), an immune regulator (enhancing NK cell activity and T-helper cell function), and a regulator of mitochondrial function and apoptosis through melatonin receptor-independent mechanisms.
Epithalon’s derivation from pineal gland extract and its consistent finding of melatonin restoration in aged animals suggests a direct action on pinealocyte function. Studies using isolated pineal glands have found that Epithalon application increases the activity of the key melatonin biosynthetic enzymes — arylalkylamine N-acetyltransferase (AANAT) and hydroxyindole-O-methyltransferase (HIOMT) — in a manner consistent with restored pinealocyte synthetic capacity rather than simple enzyme kinetics manipulation. At the whole-animal level, studies in aged rodents showed that Epithalon treatment restored the amplitude of nocturnal melatonin peaks toward levels seen in young animals, an effect that persisted for weeks beyond the treatment period in some studies. The downstream consequences of restored melatonin — improved circadian rhythm organization, enhanced antioxidant defense, better immune surveillance — represent a cascade of effects that could contribute meaningfully to the overall longevity phenotype observed in treated animals.
Oxidative stress — the imbalance between reactive oxygen species (ROS) generation and antioxidant defense capacity — is a central mechanism in the biology of aging and age-related disease. Among the most important endogenous antioxidant defenses are the superoxide dismutase enzymes, which catalyze the conversion of superoxide anion (a highly reactive and damaging radical produced as a byproduct of mitochondrial oxidative phosphorylation) to hydrogen peroxide, which can then be further detoxified by catalase and glutathione peroxidase. SOD activity declines with aging in multiple tissues, contributing to the accumulation of oxidative damage to DNA, proteins, and lipids that drives cellular dysfunction and death.
Epithalon’s effect on SOD has been documented in studies examining both expression and enzymatic activity in tissue homogenates from treated animals. Liver, kidney, brain, and immune tissues from Epithalon-treated aged animals consistently show higher SOD activity compared to untreated controls, with the magnitude of increase roughly proportional to the age-related deficit in the control group — consistent with a restoration of youthful antioxidant capacity rather than supraphysiological stimulation. The mechanism is proposed to involve gene regulatory elements upstream of the SOD1 and SOD2 promoters that are responsive to the tetrapeptide, though the precise transcription factor interactions have not been fully characterized at the structural level. The interaction between SOD upregulation and telomere maintenance is mechanistically important: oxidative DNA damage accelerates telomere shortening both by directly damaging telomeric repeats (which are particularly sensitive to oxidative lesions due to their guanine-rich composition) and by increasing the rate of cell division required for tissue repair, consuming telomere reserves faster. Epithalon’s combined SOD-upregulating and telomerase-activating effects may therefore be synergistic in preserving telomere integrity.
The foundational evidence for Epithalon’s telomere effects comes from a series of studies published primarily by Khavinson’s group over two decades. The cell culture work is mechanistically the most direct: human diploid fibroblast cultures, which have well-characterized replicative senescence timelines, were treated with Epithalon (typically at concentrations of 0.1-10 nM) and monitored for replicative capacity, telomerase activity, and telomere length over extended culture periods. Treated cultures consistently exceeded the replicative lifespan of untreated controls from the same donor, reaching 10-20 additional population doublings before entering senescence — a result consistent with Hayflick limit extension through telomerase activation.
Telomere length measurements using FISH-based telomere fluorescence intensity methods and Southern blot terminal restriction fragment analysis found that mean telomere length in Epithalon-treated cultures was significantly longer than in age-matched untreated controls (i.e., controls at the same culture passage), confirming that the extended replicative capacity was associated with genuine telomere maintenance rather than an artifact of measurement. Animal studies extended these findings in vivo: aged rodents treated with Epithalon showed longer mean telomere lengths in lymphocytes, liver cells, and other dividing tissues compared to untreated aged controls, with values approaching those measured in young (6-month-old) animals. These in vivo findings are particularly striking because they imply that Epithalon can reverse age-related telomere attrition in living organisms, not merely slow it in isolated cell cultures.
A substantial and relatively independent body of Epithalon research focuses on retinal health, with particular attention to age-related and degenerative changes in the retinal pigment epithelium (RPE) and photoreceptors. This application was motivated by the observation that retinal tissue is among the most metabolically active in the body, generates high levels of reactive oxygen species as a byproduct of phototransduction, and is particularly vulnerable to age-related degeneration — making it a relevant target for a compound combining antioxidant and anti-senescence effects.
Studies in the OXYS rat model, which spontaneously develops retinal degeneration similar in character to age-related macular degeneration, found that Epithalon treatment significantly reduced the rate of photoreceptor loss and preserved retinal function as measured by electroretinography. Treated animals maintained significantly higher amplitudes of both a-wave (photoreceptor origin) and b-wave (bipolar cell origin) ERG responses compared to untreated OXYS controls, consistent with preserved retinal architecture. Histological analysis of retinal sections showed reduced vacuolization and degeneration of RPE cells, better preserved outer segment structure in photoreceptors, and reduced accumulation of lipofuscin — a fluorescent waste product of retinal metabolism that accumulates with aging and is a hallmark of RPE dysfunction in macular degeneration. These findings from an animal model with high translational relevance have made Epithalon an active area of interest in retinal neuroprotection research, with clinical investigators exploring its potential application alongside or as an adjunct to established retinal protective strategies.
Among the most discussed data in the Epithalon literature are the longevity studies conducted by Khavinson’s group in rodents, which have reported lifespan extension in multiple experiments across different strains and species. In CBA mice — a commonly used inbred strain with well-characterized natural lifespan — Epithalon treatment initiated in middle age (14 months, when natural lifespan is approximately 24-26 months) extended mean lifespan by approximately 12% and maximum lifespan (measured as the age at which the last surviving animals died) by 20-35% compared to untreated controls. These are substantial magnitudes by the standards of longevity pharmacology research.
Cancer incidence data from these studies deserve particular attention: the treated groups showed significantly lower rates of spontaneous tumor development (primarily hepatocellular carcinoma and lymphoma, the dominant spontaneous tumor types in these strains) compared to controls. This finding connects mechanistically to both the telomere biology — chromosomal instability from critically short telomeres is a driver of oncogenic transformation — and the melatonin restoration data, since melatonin has well-established anti-tumor properties through multiple mechanisms including immune enhancement and direct anti-proliferative effects. Similar longevity findings were reported in Drosophila melanogaster models, where Epithalon treatment extended mean lifespan of fruit fly populations by approximately 16%, providing cross-species evidence that the effect is not a strain-specific artifact. Replication of these findings under fully blinded, independently conducted conditions remains an important unmet need in this research area.
The most ambitious and clinically relevant Epithalon research involves long-term observational and intervention studies in elderly human subjects, conducted by Khavinson’s group in collaboration with clinical gerontology centers in St. Petersburg. The landmark study enrolled 266 elderly men (aged 60-80 years at enrollment) and followed them with or without Epithalon treatment over a period of 6-8 years, assessing mortality, cancer incidence, and a range of biological aging biomarkers. The Epithalon-treated group received treatment courses (subcutaneous injections over 10 days) at approximately 6-month intervals throughout the study period.
Results reported by the investigators showed that the Epithalon group had significantly lower mortality over the follow-up period (approximately 28% lower than the control group), lower cancer incidence, and better-preserved immune function parameters including T-lymphocyte count, NK cell activity, and lymphocyte proliferative responses to mitogens. Biological aging markers including mean telomere length in peripheral blood lymphocytes also showed slower decline in the treated group compared to controls. These are striking findings if validated; however, important methodological limitations apply. The study was not conducted under the blinding and randomization standards required for high-confidence causal inference; patient selection, concurrent interventions, and socioeconomic confounds are not fully controlled in the published descriptions; and independent replication by groups unaffiliated with the original investigators has not been published. These limitations are acknowledged without dismissing the findings, which remain compelling as hypothesis-generating data warranting rigorous confirmatory research.
A consistent theme across multiple Epithalon studies is its capacity to restore age-associated disruptions in circadian and endocrine physiology. Aging produces characteristic changes in biological rhythms: the amplitude of the melatonin circadian cycle decreases, the timing of cortisol secretion shifts earlier, and the coordination between different hormonal rhythms (melatonin, growth hormone, cortisol, body temperature) that characterizes healthy circadian function deteriorates. These disruptions are not merely inconvenient — circadian dysregulation is increasingly recognized as a driver of metabolic disease, immune dysfunction, accelerated cognitive decline, and cancer risk.
Studies in aged rodents found that Epithalon treatment significantly restored melatonin circadian amplitude, with night-time peaks approaching those of young animals after treatment courses. Cortisol rhythm normalization was also documented — a shift toward less nocturnal cortisol and more appropriately timed morning peaks. Growth hormone pulsatility, which is dramatically reduced in aging, showed partial restoration in Epithalon-treated animals. Together, these findings suggest that Epithalon acts on the neuroendocrine pacemakers — the hypothalamic suprachiasmatic nucleus and pineal gland — in a manner that restores youthful synchronization of biological clocks, with potential downstream benefits extending across the many physiological processes those clocks control.
The dosing regimens used in published Epithalon research fall into a relatively consistent range despite varying administration routes. The most commonly used research doses in animal studies are 0.5-3 mg/kg subcutaneous, with human equivalent doses (using body surface area scaling) in the range of 0.1-0.5 mg/kg — approximately 5-40 mg for an adult human. In Khavinson’s human studies, the most commonly reported regimen was 5-10 mg administered by subcutaneous injection daily for 10 days, repeated every 4-6 months. Some protocols have used lower daily doses (1-2 mg) for shorter treatment windows, while others exploring intensive longevity applications have used 10 mg/day for 10-day courses. The Peptides Helper dosing calculator can assist with weight-adjusted research dose calculations, though the relative scarcity of dose-ranging data for Epithalon compared to more extensively studied peptides means that the optimal dose-response relationship is not as precisely characterized.
Subcutaneous injection is the administration route used in the human Khavinson studies and the majority of animal research, and it represents the route with the most direct published evidence for biological activity in vivo. Given Epithalon’s small size (390 daltons, tetrapeptide), it is one of the few peptides in this category where alternative routes beyond subcutaneous injection have some theoretical basis for reasonable bioavailability. Intranasal administration has been studied in some animal experiments and reported to be effective, and there is research interest in oral formulations — though peptide degradation in the GI tract remains a challenge, and oral Epithalon’s bioavailability has not been rigorously quantified in published pharmacokinetic studies. For reliable systemic exposure, subcutaneous injection remains the most evidence-supported choice. Reconstitution using bacteriostatic water in amber vials, stored at 2-8°C after preparation, follows standard peptide reconstitution protocols; the peptide database provides storage stability references for this compound class.
The most studied long-term administration pattern involves course-based treatment: 10 consecutive days of daily injection, followed by a rest period of several months before the next course. This pattern was used in the flagship human longevity study (6-month intervals between courses) and in multiple animal aging studies. The rationale for course-based rather than continuous treatment reflects both practical considerations (injection burden) and the observed biology — many of Epithalon’s effects, particularly telomere elongation and melatonin normalization, appear to persist well beyond the acute treatment window, suggesting that periodic “resetting” may be sufficient to maintain benefit. Some investigators have used 3-month intervals between courses for more intensive research protocols. For detailed cycling protocol discussion based on available literature, the AI coach can provide a literature-referenced overview.
Epithalon is typically supplied as a lyophilized powder in vials of 5-20 mg. Reconstitution with 1 mL of bacteriostatic water yields a concentration of 5-20 mg/mL depending on vial size, from which individual doses can be drawn. For a standard 10 mg/day dose drawn from a 10 mg/mL solution, 1 mL per injection is standard. The tetrapeptide’s small size and water solubility make reconstitution straightforward compared to larger, more hydrophobic peptides — gentle swirling without agitation is sufficient to achieve complete dissolution. Once reconstituted, solutions should be stored at 2-8°C and used within 30 days. The lyophilized powder, stored at -20°C in a desiccated, light-protected container, maintains stability for 12-24 months based on standard peptide stability data. Use the dosing calculator for preparation volume and concentration calculations specific to your research protocol.
The published safety literature on Epithalon presents a remarkably clean adverse event profile, with no serious adverse events attributed to the compound in the available clinical study reports. Local injection site reactions — mild erythema, tenderness, or induration — are the most consistently reported adverse effects, occurring in a minority of subjects in injection-based studies. These reactions are typical of subcutaneous peptide injections generally and resolve spontaneously without treatment. Systemic adverse effects have not been a prominent feature in published accounts: no cardiovascular, hepatic, renal, or hematological toxicity signals have appeared in the laboratory monitoring data reported by Khavinson’s group in human studies, and no deaths or serious adverse events attributed to Epithalon were reported in the 6-8 year longevity study. Subjective adverse effects such as headache, fatigue, or mood changes were not highlighted in published study reports, suggesting they were either absent or not systematically collected.
The most scientifically important safety consideration for any telomerase-activating compound is the theoretical possibility that increasing telomerase activity could facilitate cancer cell immortalization. Telomerase reactivation is one of the hallmarks of cancer — approximately 85-90% of human cancers upregulate telomerase to maintain the telomere length that enables unlimited replication. The concern is therefore: could Epithalon’s telomerase-activating effect in normal somatic cells also enhance the growth of existing subclinical cancer clones or increase mutation-driven cancer initiation?
This concern is theoretically real and deserves serious consideration. The counterarguments from Khavinson’s research are primarily empirical: the animal and human studies show lower cancer incidence in Epithalon-treated groups rather than higher, the opposite of what the telomerase-cancer concern would predict. The proposed resolution is that maintaining telomere integrity in normal cells actually reduces the chromosomal instability that drives cancer initiation — critically short telomeres produce the chromosomal rearrangements and genomic instability that are early events in carcinogenesis. So Epithalon’s anti-cancer phenotype in published studies may reflect genuine telomere-stabilizing protection against cancer initiation. However, in individuals with established cancer or with very high genetic cancer risk, the theoretical pro-growth effect of telomerase activation on existing malignant cells remains a potential concern that published data do not definitively rule out, and caution is warranted.
The critical limitation of Epithalon’s safety literature is that virtually all of it originates from a single research group. While Khavinson’s publications are peer-reviewed and published in indexed journals, the absence of independent replication of either efficacy or safety findings makes high-confidence safety conclusions premature. Key uncharacterized areas include: pharmacokinetic data in humans (no published Tmax, Cmax, half-life, or volume of distribution data from rigorous human PK studies); drug interaction potential with commonly co-administered compounds; safety in pediatric, pregnant, or lactating populations (unstudied and contraindicated by standard precautionary principles); and the safety of very long-term use (years to decades) at the doses proposed for longevity applications. Researchers working with Epithalon should review the original literature directly, assess the methodological quality of each study independently, and monitor published updates through the Peptides Helper database.
Yes — Epithalon and Epitalon are different transliterations of the same compound from Russian, reflecting the absence of a single standardized romanization for the Cyrillic name. Both spellings refer to the identical tetrapeptide Ala-Glu-Asp-Gly. In Russian scientific literature, the compound is written as “эпиталон” (epithalon), and you will encounter both “Epithalon” and “Epitalon” in English-language sources depending on the transliteration convention used by the particular journal or author. When searching the literature or the peptide database, using both spellings ensures complete coverage.
Epithalamin is the complex polypeptide extract from bovine pineal glands that was studied extensively by Khavinson’s group before Epithalon was synthesized. It contains a mixture of peptide fragments from the pineal proteome, of which Ala-Glu-Asp-Gly (Epithalon) was identified as a primary active component. Epithalamin showed similar biological effects to Epithalon in animal studies — lifespan extension, melatonin normalization, immune enhancement — but as an extract from animal tissue it carries issues of batch-to-batch variability, immunogenicity risk from bovine peptide sequences, and supply chain limitations. Epithalon, as a synthetic tetrapeptide, offers chemically defined composition, reproducible potency, and the ability to produce research-grade material without animal sourcing. The synthetic analog approach also enables structure-activity relationship studies that are impossible with a crude extract.
The cell culture studies showing telomere elongation in Epithalon-treated cells, and the animal studies showing longer telomeres in treated aged animals, demonstrate that Epithalon can reverse telomere shortening at the cellular level. Whether this translates to reversal of organismal aging — as opposed to slowing its progression — is a different and more complex question. The longevity data suggest extension of maximum lifespan in treated animals, which would be consistent with a genuine anti-aging effect rather than merely a health-span effect. But “reversal of aging” is a loaded and scientifically contested phrase: aging involves many parallel and interconnected processes (epigenetic changes, mitochondrial dysfunction, protein aggregation, and others) not all of which are addressed by telomere maintenance. A more accurate framing is that Epithalon appears to address one of the most significant molecular mechanisms of cellular aging, with evidence of downstream benefits across multiple aging-related endpoints — which is genuinely remarkable but not necessarily equivalent to comprehensive aging reversal.
Lyophilized (freeze-dried) Epithalon powder should be stored at -20°C in a desiccated, light-protected container — a standard peptide storage protocol. Under these conditions, shelf life of 12-24 months or longer is supported by standard peptide stability data. Once reconstituted, the solution should be stored at 2-8°C (standard refrigerator temperature) in an amber or foil-wrapped vial to protect from light, and should be used within 30 days. Avoid repeated freeze-thaw cycles of reconstituted solution, as these degrade most peptides. Because Epithalon’s tetrapeptide structure is relatively simple and lacks disulfide bonds or complex tertiary structure, it is generally more stable than larger, more structurally complex peptides — but standard peptide handling precautions remain important.
The primary human evidence comes from Khavinson’s longitudinal studies in elderly men, which reported significant differences in mortality, cancer incidence, immune function, and telomere length over 6-8 year follow-up periods. Additional human data come from shorter-term studies examining endocrine markers (melatonin, cortisol, sex hormones) and immune parameters. These studies are published in peer-reviewed journals but have not been independently replicated, and the methodological limitations described in the Safety section apply. The human evidence is therefore more hypothesis-generating than definitively confirmatory, and claims that Epithalon “extends human lifespan” cannot be supported at the level of evidence required for that conclusion. What can be said is that the available human data are consistent with meaningful biological activity at doses studied and do not reveal safety signals that would argue against continued research investigation.
The retinal research on Epithalon — particularly the findings in the OXYS rat model of spontaneous retinal degeneration — is directly relevant to age-related macular degeneration (AMD) research, the leading cause of irreversible vision loss in elderly individuals. The mechanisms implicated in AMD (oxidative stress to RPE cells, photoreceptor degeneration, lipofuscin accumulation) are precisely those shown to be attenuated by Epithalon in the animal studies. No clinical trials of Epithalon in human AMD have been published, but the preclinical signal is sufficiently compelling to motivate clinical investigation. This is an area where the AI coach can provide a current literature summary and help identify any emerging human data that has appeared in the research literature.
Epithalon and melatonin have overlapping goals — both support circadian rhythm integrity and antioxidant defense — but through different mechanisms. Melatonin supplementation provides exogenous melatonin receptor ligand, producing immediate circadian-supporting and antioxidant effects that last for the duration of metabolic clearance (typically 4-6 hours). Epithalon acts on pinealocyte function to restore endogenous melatonin production, which has a longer-lasting effect but operates indirectly and with a longer time to effect. The two approaches could theoretically be complementary: exogenous melatonin addresses the immediate deficit while Epithalon works to restore underlying pineal function. No published study has directly examined the combination, and no known adverse interaction has been identified based on their respective mechanisms. However, this combination has not been formally studied, and individuals considering concurrent use should discuss the rationale and available evidence with a knowledgeable research collaborator.
Epithalon has not undergone the Phase 1, Phase 2, and Phase 3 clinical trial process required for FDA or EMA pharmaceutical approval. The research base supporting Epithalon is primarily from a single Russian research group, has not been replicated independently under controlled conditions meeting Western regulatory standards, and has not been submitted to regulatory agencies for review. The commercial motivation for pursuing Western regulatory approval would require a pharmaceutical company willing to invest in the extensive and expensive clinical trial program needed, and no such program has been publicly announced. The compound’s patent status also affects commercial incentive — a simple tetrapeptide may be difficult to patent in ways that support exclusive commercial return on clinical development investment. In the US, Epithalon exists in a research compound category without approved drug status, accessible for research purposes but not for any therapeutic use outside the investigational framework.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.